Valeant Gives Mixed Response To Potential Allergan/Salix Deal
This article was originally published in The Pink Sheet Daily
Valeant and activist investing partner Bill Ackman took opposite approaches to the news that Allergan may be pursuing Salix buyout as a defensive move to block a takeover.
You may also be interested in...
With new retreatment data in hand, Salix is again pursuing a supplemental claim for the antibacterial Xifaxan, while Actavis is seeking approval of eluxadoline, a new molecular entity with dual opioid receptor activity.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.